RE Coleman

66P Impact of MAF selection of patients for adjuvant bisphosphonate therapy and comparison with current clinical guidance

RE Coleman, Alexander Paterson, Roger R. Gomis

gb, es (code pays fourni par la source)

182P Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study

H. S. Rugo, K. Drumea, S.C. Lee, M. Campone et autres

us, il, sg, fr, be, es, no, ch, gb (code pays fourni par la source)

372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Alessandro D. Santin, Ignace Vergote, Antonio González-Martı́n, Kathleen N. Moore et autres

us, es, de (code pays fourni par la source)

15 Randomized double-blind placebo controlled trial of frontline maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: efficacy assessment in BRCA1/2-wt patients

Rodney P. Rocconi, E.A. Grosen, Sharad Ghamande, John K. Chan et autres

us (code pays fourni par la source)

Demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma: a UK population study

Philip Savage, Matthew Winter, Victoria Parker, V Harding et autres

OBJECTIVE: To investigate the demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma. DESIGN: A retrospective national population-based study. SETTING: UK 1995-2015. POPULATION: A total of 234 women with a diagnosis of gestational choriocarcinoma, in the absence of a prior molar …

gb (code pays fourni par la source)

Testosterone Replacement in Young Male cancer Survivors (TRYMS): A six-month double-blind randomised placebo-controlled study

Jennifer Walsh, Henry Marshall, A. Ian Smith, DM Greenfield et autres

Abstract P2-12-01: Dose- and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the STAKT randomized, placebo controlled pre-surgical study

Julia M.W. Gee, RE Coleman, Kwok‐Leung Cheung, Abigail Evans et autres

Abstract Background: Capivasertib (AZD5363), an AKT1,2,3 inhibitor, significantly improved progression-free and overall survival when added to paclitaxel in triple negative breast cancer (BC) patients (Schmid et al. ASCO 2018). We have previously reported in STAKT, robust target inhibition at 480mg BD versus …

gb (code pays fourni par la source)

Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment

Penelope D. Ottewell, DV Lefley, Katy Freeman, WM Gregory et autres

Abstract Background: Breast cancer bone metastases are incurable and new therapeutic targets needed. After homing and colonising bone, cancer cells remain dormant, until signals from the microenvironment stimulate their proliferation to form overt metastases. We have recently identified interleukin-1B (IL-1B) as a …

ch, gb (code pays fourni par la source)

Abstract P4-04-06: AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers

JFR Robertson, RE Coleman, Kwok‐Leung Cheung, Abigail Evans et autres

Abstract Background: AKT is an important intracellular control point through which Type 1 growth factors and IGFR signal. Mutations in PIK3CA, AKT and PTEN are prevalent in estrogen receptor positive (ER+) breast cancer (BC) and have been implicated in resistance to endocrine …

gb (code pays fourni par la source)

Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

GF Fleming, PA Francis, István Láng, Eva Ciruelos et autres

Abstract Background: The primary results of SOFT at 5.6 years median follow-up found adding OFS to T did not provide a significant benefit in the overall study population of premenopausal women with HR+ BC (Francis et al, NEJM 2015). For those women …

be, ch (code pays fourni par la source)

Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial

AO Oke, Jill Knox, J Tan, Benoit Aigret et autres

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

HS Rugo, KC Drumea, Mario Campone, Agustí Barnadas et autres

Abstract Background: Treatment options for bone-dominant metastatic breast cancer (MBC) are limited. Radium-223, a first-in-class α emitter with a targeted antitumor effect on bone metastases (mets), was well tolerated and reduced bone biomarker levels in a phase 2 study in patients with …

us, il, es, gb, fr (code pays fourni par la source)